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Abstract
Objectives: This study aims to evaluate the effectiveness of periodontal therapy combined with tacrolimus in the 
suppression of gingival overgrowth (GO) and the effect on GO of changing from cyclosporin A to tacrolimus.
Patients and Methods: Sixteen renal transplant patients, averaging 52 years of age, whose kidney function was 
stable and were receiving treatment with cyclosporin A, were randomly assigned to one of two groups. In the 
experimental group, patients were instructed in oral hygiene and underwent periodontal treatment, whereas in the 
control group, only oral hygiene instructions were given. After the first visit and the change of medication from 
cyclosporine to tacrolimus in both groups, periodic clinical revisions were carried out for 3 months in order to 
assess the evolution of GO.
Results: All patients showed a progressive decrease in GO. There were no statistically significant differences 
between the two groups (p>0.05). A greater decrease in GO occurred within the first month after changing the 
medication.
Conclusions: No improved effectiveness in reducing GO was observed for periodontal therapy in combination 
with tacrolimus. Tacrolimus is an alternative to cyclosporine when attempting to avoid GO in patients with kidney 
transplants.
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Introduction 
Cyclosporin A is a lipophilic cyclic oligopeptide  ex-
tracted from a fungus (Tolypocladium inflatum Gams) 
with immunosuppressant action widely used to inhibit 
organ transplant rejection, and in the treatment of au-
toimmune diseases such as insulin-dependent diabetes 
mellitus, Behçet disease, psoriasis, lupus erythemato-
sus or rheumatoid arthritis (1). 
Adverse effects associated with immunosuppressive 
therapy with cyclosporin A have been reported, such as: 
Hypertension, usually associated with fluid retention; 
nephrotoxicity, by altering the balance between pros-
tacyclin and thromboxane A2, liver toxicity, neurotoxi-
city and diabetes mellitus. In addition, patients treated 
with this drug have a higher incidence of skin tumors 
and lymphomas, particularly Kaposi’s sarcoma. 
Adverse oral effects are hypertrophy of lingual fungi-
form papillae and gingival overgrowth (GO) (2,3). Spo-
lidorio et al. (4), compared the oral health of patients 
treated with cyclosporine or tacrolimus and found cases 
of squamous cell carcinoma, herpes simplex, GO and 
candidiasis (found to be the most common oral patho-
logy) in the group of patients treated with cyclosporine. 
Clinically, GO may manifest as non-inflamed, firm, 
fibrous gingiva, or with an edematous, erythematous, 
hemorrhagic appearance in cases associated with gingi-
vitis induced by bacterial plaque (5). The location of the 
plaque and gingivitis is not consistent with the distribu-
tion of the GO, suggesting a possible influence of local 
anatomical features (insertion of frenum, tongue) in the 
development of GO (6).
No consensus exists in the literature on the relationship 
between dosage and the concentration of cyclosporin A 
and the development of GO. Daley et al. (7) suggested 
that a concentration threshold of cyclosporine had to be 
exceeded for GO to appear, while higher concentrations 
of the drug did not increase the severity of the GO. 
Histologically, GO is characterized by areas of dense 
collagen and degeneration associated with an inflam-
matory infiltrate of lymphocytes and plasma cells. Like-
wise, there is no evidence of an increase in the number 
of fibroblasts (8).
In contrast, the immunosuppressant, tacrolimus, has 
been used successfully in liver and kidney transplants 
with no adverse effects on the gingiva. However, it is as-
sociated with an increased incidence of post-transplant 
diabetes mellitus when used at high doses, in conjunc-
tion with corticosteroids and in patients older than 45 
years (9). 
A rapid resolution of GO has been observed after con-
version from cyclosporin A to tacrolimus. Tacrolimus 
is a macrolide derived from a fungus (Streptomyces 
tsukubaensis), introduced in 1987 to prevent rejection 
of transplanted organs. It displays immunosuppressive 
characteristics similar to those of cyclosporine, but is 
between 10 and 100 times more effective in inhibiting 
IL-2 and interferon gamma (IFN-γ) production (10). 
The adverse effects of tacrolimus are similar to those of 
cyclosporine, and associated nephrotoxicity and hyper-
tension are lesser severe. This may, therefore, be a good 
alternative to cyclosporin A when avoiding GO in  renal 
transplant patients is desired. 
This paper aims to evaluate the efficacy of tacrolimus 
therapy in reducing GO in renal transplant patients pre-
viously treated with cyclosporin A, as well as the effect 
of conventional periodontal treatment on the amount of 
decrease.
Patients and Method 
We performed a prospective randomized clinical trial 
in which 16 patients were included (10 males and 6 
females) aged between 31 and 67 years, having un-
dergone kidney transplant at the Bellvitge Hospital in 
L’Hospitalet de Llobregat (Barcelona). Renal function 
of all patients was stable and they were under immuno-
suppressive therapy with cyclosporin A.
Patients who had undergone periodontal treatment 
within the previous 6 months, smokers, those treated 
with hydantoin, nifedipine, amlodipine, verapamil and 
diltiazem and / or with an associated systemic disease 
that could have a known affect on the gingiva such as 
thrombocytopenic purpura, leukemia or diabetes me-
llitus, were excluded from the study. 
All patients included in the study were required to have 
at least 10 anterior teeth. 
After being informed of the nature of the study and hav-
ing obtained informed consent to participate in the re-
search, patients were randomly assigned to two groups. 
On the first visit, the experimental group was instructed 
in oral hygiene, and periodontal treatment was conduct-
ed consisting of the removal of plaque and supragin-
gival calculus; while in the control group, only verbal 
instructions for oral hygiene were given. After the first 
visit, cyclosporin A was substituted by tacrolimus in 
all patients. Follow-up was performed monthly for 3 
months. All examinations were carried out by two den-
tists  at the Oral Surgery Service of the Dental Clinic at 
the University of Barcelona. 
At the first visit and on all subsequent checkups, GO was 
assessed in the incisor-canine region in both jaws using 
the Angelopoulus and Goaz, and M and B indexes.
The first assesses vertical or apical-coronal GO, using 
values ranging from 0, when GO is absent; to 3, if the 
enlargement is severe and covers more than two thirds 
of the tooth crown. Six points are assessed at each tooth: 
middle, distal and mesial at the facial and palatal or lin-
gual aspect. 
The second evaluates overgrowth in a horizontal or 
buccolingual direction of the interdental papilla both on 
the buccal and palatal or lingual side. Values range from 
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0 to 2, with a thickness of less than 1 mm interdental 
papilla for the value 0,1 for interdental papilla thickness 
between 1 and 2 mm, and 2 for interdental papilla thick-
ness greater than 2 mm. 
Statistical analyses were carried out using the follo-
wing non-parametric tests: Mann-Whitney, Friedman 
and Wilcoxon. In all cases, values of p<0.05 were con-
sidered statistically significant.
Results 
The average age of the patients included in the study 
was 52 years, 62% were men and 38% women. During 
the study, one of the 16 patients was lost suffering from 
hyperglycemic coma one month after the administration 
of tacrolimus and the suppression of cyclosporin A. 
All patients showed a progressive decrease in GO. There 
were no statistically significant differences (p>0.05) bet-
ween the experimental and the control group. Howe-
ver, neither group obtained a complete remission. (Fig.1 
and 2) show a patient who presented almost complete 
remission of his GO after switching to tacrolimus as 
monotherapy. 
Differences in the Angelopoulus and Goaz index were 
detected only at 3 buccal points two months after the 
change in medication. However, in the M and B index, 
5 of the 6 points that showed differences between the 
experimental and the control group were palatal; most 
of these differences were also seen at the 2 month exa-
mination.
The largest decrease in GO occurred during the first 
month after the change in medication. Thereafter, the 
GO stabilized, but with continued trend for improve-
ment. At the second and third month follow-up, there 
were no statistically significant changes, except for the 
interdental papilla distal to 3.3 in a buccolingual direc-
tion (M and B index) in the control group.
On reviewing the evolution of GO from the first visit to 
the last examination at 3 months after changing medica-
tion, using the Angelopoulus and Goaz index no statisti-
cally significant changes (p>0.05) were observed in any 
of the buccal, palatal or lingual midpoints (Table 1).  
A greater decrease in GO was observed at the distal and 
mesial points in both maxilla and mandible.
Likewise, the reduction of GO in the experimental 
group and the control group was unequal between the 
mandible and the maxilla. In the mandible, the points 
evolved in a similar manner in both groups, whereas 
in the maxilla the experimental group presented more 
points with favorable results. These were located mostly 
in the second quadrant.
Discussion
Gingival overgrowth is a commonly associated compli-
cation with the use of drugs such as cyclosporin A, which 
can cause oral and psychological changes in the patient. 
Tacrolimus is a therapeutic alternative to cyclosporin A 
(11), having some similar, although decreased, adverse 
effects. In the study by James et al. (12), there was an 
Fig. 1. Gingival overgrowth 
at the first visit.
Fig. 2. The same patient 3 
months after changing from 
cyclosporin A to tacrolimus.
Angelopoulus and Goaz Index M and B Index
Mean cases Mean controls Mean cases Mean controls
12MBv3*    0 0.75 11DPv2**     0.13 0.75
11DBv3      0 0.75 21MPv2      0.13 0.63
42DBv3      0 0.63 22MPv2      0 0.50
21MPv3      0 0.50
22MPv3      0 0.50
32MPVv3    0.13 0.75
*v3: 3th visit
**v2: 2th visit
(M,D,V,P): mesial, distal, bucal y palatal
Table 1. Results of measurements using Angelopoulus and Goaz Index, and M and 
B Index (Mann-Whitney Test), made between the study group and the control group 
from the first to the last visit.
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increase in gingival growth of 24.9% to 82.3% with the 
change from tacrolimus to cyclosporine. 
GO affects the attached gingiva, it may extend corona-
lly and interfere with occlusion, mastication and phona-
tion. It usually begins in the interdental papilla during 
the first 3 months of treatment with cyclosporin A (13). 
However, some authors have only seen GO in patients 
treated with cyclosporin A for more than 3 months. In 
our study, GO evaluated using the Angelopoulus and 
Goaz index was less than 1, and therefore did not inter-
fere with occlusion. 
GO in patients treated with cyclosporin A is more se-
vere in areas with plaque, calculus, subgingival restora-
tions, as well as in wearers of orthodontic appliances 
and prostheses (7). However, the role of plaque in GO 
induced by cyclosporin A remains uncertain. Alfonso et 
al. (13), in a study of 40 patients, found no statistically 
significant relationship between GO and the plaque in-
dex. The elimination of bacterial plaque appears to have 
little relevance in the prevention of GO. In our study the 
presence of plaque was not associated with an increase 
in GO, but did have an effect on its evolution. 
The incidence of GO in patients who continue treat-
ment with cyclosporin A varies from 13% to 81%. The 
reasons for this wide margin are, the nature of the di-
sease treated, the patient’s age, the dose and duration 
of treatment with cyclosporin A, the combined use of 
other drugs and genetic predisposition. In a study by 
Vescovi et al. the prevalence of GO was 47% in patients 
taking cyclosporin A with azathioprine, and 50% for 
those who only took cyclosporin A. In our study the 
incidence of GO in patients taking cyclosporin A was 
73%. The prevalence and severity of GO is increased 
in individuals who take cyclosporin A with calcium 
channel-blocking agents (4,6). James et al. (14) in their 
study concluded that coadministration of cyclosporin 
A with amlodipine produces a greater GO (72%) than 
cyclosporin A with nifedipine (53%). In our study, all 
patients taking additional medications were excluded to 
avoid bias in the results.
Daley et al. (15) demonstrated that children and ado-
lescents were more susceptible to gingival changes in-
duced by cyclosporin A. As our sample did not include 
children or adolescents, our results cannot be compared 
with these facts.
Although GO caused by the intake of cyclosporin 
A may be found in any region of the oral cavity, the 
changes are most pronounced in the anterior area of the 
mandible and on the buccal side. A study conducted on 
194 patients undergoing an organ transplant confirmed 
the predilection of GO for the vestibular surface, but no 
statistically significant differences were found between 
maxilla and mandible. Said GO was higher in the ca-
nine region than in the area of the central incisors (6). 
In our study, however, the decrease of GO in the ex-
perimental group and the control group was not equal 
in the mandible and the maxilla. In the mandible, points 
evolved similarly in both groups, whereas in the maxilla 
the experimental group presented more points with fa-
vorable results. Furthermore, no statistically significant 
differences were observed in the vestibular points, the 
more pronounced changes being in the mesial and distal 
points. The most favorable evolution was found in the 
second quadrant in the experimental group. 
The removal of the inducing drug, in this case cy-
closporin A, would be the ideal choice, since it has been 
shown that the GO disappears completely 3-12 months 
after drug suspension. However, this measure is not al-
ways possible in patients with kidney transplants. In our 
study, the largest decrease in GO occurred in the first 
month after change in medication. 
There have been cases reported in which there was a re-
mission of GO after reducing the dosage of cyclosporin 
A, and without recurrence after a follow-up of 2 years. 
This finding raises the possibility that a reduction in the 
dosage of cyclosporin A below a threshold concentra-
tion may resolve the GO (16). 
In a study by Oliveira et al. (17) to determine the prev-
alence and severity of GO in patients treated with ta-
crolimus or cyclosporin A; in patients treated with ta-
crolimus a 17.9% prevalence of GO was noted, while in 
the group medicated with cyclosporin A this was 38.1%. 
However, no statistically significant differences were ob-
served between the clinical variables (plaque index and 
papillary bleeding index) in either group. In the study 
by Ellis et al. (18) on the prevalence of gingival growth 
in transplanted patients, the GO was rated as 14.15% in 
patients treated with tacrolimus and as 22.4% in patients 
treated with cyclosporin A, proving once again that ta-
crolimus produces less GO than cyclosporin A. They 
also identified independent variables that reduce GO, 
the most relevant being the age and combined adminis-
tration of azathioprine. Other variables that increased 
GO were medication combined with calcium channel 
blockers, a high plaque index, papillary bleeding, and 
previous medication with cyclosporine (18). 
The results obtained in this study are consistent with 
others previously published, making it possible to state 
that the use of tacrolimus is associated with a substan-
tial reduction in the severity of GO, although the reduc-
tion is not complete in most cases (12). On the other 
hand, we found recent studies that conclude that there is 
no statistically significant difference in the incidence of 
GO in patients treated with tacrolimus compared with 
others treated with cyclosporine 90 days after transplan-
tation (19). A study by Hernandez et al. (20) confirmed 
that this reduction was already evident 8 weeks after the 
conversion from cyclosporine to tacrolimus, coinciding 
with the results of our study. 
The partial disappearance of GO may be explained by 
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the short follow-up period on the patients in our study. 
Three months is not sufficient to achieve a physiologi-
cal remodeling, which involves the removal of a large 
number of macromolecules of the extracellular matrix. 
In spite of this, all patients expressed their satisfaction 
with the elimination of the functional and aesthetic ir-
ritation following change in medication. 
Previous studies that have assessed the effects of peri-
odontal treatment on GO showed conflicting results. 
Kantarci et al. (1) claimed that good plaque control 
through proper oral hygiene, and periodontal treatment 
which consists in removing supra- and sub-gingival 
plaque and calculus, should be the first step in the clini-
cal management of GO with cyclosporin A. Scaling and 
root planing eliminated the inflammatory component of 
the GO, the fibrous component representing 60% of the 
dysmorphism. In our study, patients in the experimental 
group presented better results in the maxilla than the 
control group, while in mandible there were no signifi-
cant differences. 
The conversion from cyclosporin A to tacrolimus pro-
duces a resolution of GO within the first month.
In our study, no greater efficacy was proven for con-
ventional periodontal treatment in combination with 
the administration of tacrolimus, in comparison with 
the removal of cyclosporin A in favor of tacrolimus as 
monotherapy for the reduction of GO.
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